Ignite Creation Date:
2024-05-06 @ 2:54 AM
Last Modification Date:
2024-10-26 @ 11:25 AM
Study NCT ID:
NCT02151526
Status:
COMPLETED
Last Update Posted:
2022-04-26
First Post:
2014-05-14
Brief Title:
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major Also Referred to as Transfusion-dependent β-Thalassemia TDT and Sickle Cell Disease
Sponsor:
bluebird bio
Organization:
bluebird bio
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-06-07
Start Date Type:
ACTUAL
Primary Completion Date:
2019-02-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-02-26
Completion Date Type:
ACTUAL
First Submit Date:
2014-05-14
First Submit QC Date:
May 29 2014
Study First Post Date:
2014-05-30
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2020-03-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-04-05
Last Update Post Date:
2022-04-26
Last Update Post Date Type:
ACTUAL